Analysis of Microtox®PD chips coated with Optimer binding agents detect 3 common variants of concern of SARS-CoV-2 virus
Deepverge PLC (DVRG.L) MicrotoxPD detects 3 COVID variants of concern
TPI provides its latest research note on DeepVerge plc (DVRG.L)
DeepVerge has released a post-31 December 2021 year-end trading update along with a statement detailing its outlook for the current year.
Deepverge PLC (DVRG.L) unaudited 2021 revenue growth exceeds 108% to £9.33m
Skin Trust Club to launch video medical consultations and diagnostic service
Deepverge PLC (DVRG.L) Microtox CTM installed ahead of Winter Olympics
Microtox water testing equipment installed ahead of Beijing 2022 Winter Olympics
Labskin Ezine Christmas 2021
Dear Gerard 2021 is coming to a close, and the Labskin Team would like to take this opportunity to thank partners and clients for their continued support. It was another eventful
Think Global – Act Local! Helping To Solve A Pandemic Puzzle
Testing In Public Water Systems Testing for coronavirus has become a day-to-day occurrence across the globe since the pandemic began in 2019. Testing for traces of the virus in public
Deepverge PLC (DVRG.L) Amends to Agreement with Microsaic Systems; RPT
Modern Water Mobile Services pandemic response detection to include mass spectrometry as part of DeepVerge and Microsaic Systems plc Technology and Commercial Agreement.
Launch of Compact Microtox® PD Surveillance Units In Q1 2022
Detects SARS-CoV-2 and a range of pathogens at local, regional and national levels
TPI provides its latest research note on DeepVerge plc (DVRG.L)
DeepVerge has announced its proposed Q1 2022 launch of compact Microtox® PD surveillance units. This upgraded system significantly expands surveillance capabilities into smaller communities and/or facilities/locations where larger groups of
Deepverge PLC (DVRG.L) Compact Microtox® PD launch scheduled for Q1 2022
Launch of compact Microtox® PD[i] surveillance units in Q1 2022
Tern PLC (TERN.L) Device Authority Strategic Investment & Funding
Device Authority Strategic Investment from Venafi, Capital Restructuring and Additional Funding
